Competing in the Global Hematology and Flow Cytometry Market, 2019-2023

Competing in the Global Hematology and Flow Cytometry Market, 2019-2023

  • July 2019 •
  • 700 pages •
  • Report ID: 4959426 •
  • Format: PDF
Competing in the Global Hematology and Flow Cytometry Market, 2019-2023

This new report contains 700 pages, 250 tables, and provides information not available from any other published source, including:
- Specimen forecasts by market segment
- Test volume forecasts by assay and market segment
- Reagent and instrument sales forecasts by market segment
- Instrument placements and installed base by manufacturer and model
- Sales and market shares of reagent and instrument suppliers

The report will help current suppliers and potential market entrants identify and evaluate emerging opportunities in the hematology and flow cytometry markets during the next five years. The report explores future marketing and technological trends in seven countries; provides market share estimates, test volume forecasts, and instrument placements; compares features of leading analyzers; profiles major competitors and emerging market entrants; and suggests specific product and marketing opportunities facing suppliers.

During the next five years, continued advances in molecular diagnostics, monoclonal antibodies, lasers and IT, as well as growing understanding of immunologic forces regulating systemic diseases, will have a profound impact on the hematology and flow cytometry markets worldwide. New molecular diagnostic and monoclonal antibody tests will facilitate existing procedures and provide basis for sensitive, specific and simple assays. The introduction of smaller and easy-to-operate laser systems will further expand applications of flow cytometry to routine clinical laboratories. Further advances in IT will reduce the cost of instrument manufacture, service warranty, and permit development of self-troubleshooting, autocalibration and other advanced features. Presently tedious analyses of chromosomal abnormalities, DNA content, and lymphocyte subsets will become more automated and routine.

Contains 700 pages and 250 tables.

Companies Profiled
Competitive Assessments

- Abbott
- Agilent Technologies
- Beckman Coulter/Danaher
- Becton Dickinson
- Bio-Rad
- CellaVision
- Horiba
- Nihon Kohden
- Ortho-Clinical Diagnostics
- Roche
- Siemens Healthineers
- Sysmex